Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial

Table 2 Summary of study cohort clinical characteristics

Case No	age	LDH	DF Duration	No organs	Organs involved	TV (cc)	RECIST
1	36	NA	1512	1	Lymph nodes (LN)	1.93	SD
2	41	NA	237	5	LN, lung, soft tissues, bowel, liver	1065.58	SD
3	58	266	252	3	Liver, bone, lung	40.39	PR
4	66	226	1765	1	lung	0.3	PR
5	67	363	109	2	LN, liver	74.2	PD
6	28	193	126	2	LN,liver	14.06	PD
7	46	484	125	3	Lung, liver, LN	445.4	PD
6	65	251	637	1	lung	5.61	PR
5	50	292	1586	2	Lung, liver	7.62	PD
10	81	548	956	3	s/c tissues, thoracic LN, intra-abdominal deposits	304.48	PD

ECOG European Cooperative Oncology Group, IQR interquartile range, LDH lactate dehydrogenase, LN lymph nodes, PR partial remission, PD progressive disease, RECIST response criteria in solid tumors, S/C subcutaneous, SD standard deviation, TV tumor volume

ISSN: 1471-2407